Expertise in
70
conditions

Dr. Mark D. Kochenderfer

Oncology
Blue Ridge Cancer Center
2013 Jefferson St SW, 
Roanoke, VA 
Accepting New Patients
Offers Telehealth
Expertise in
70
conditions
Blue Ridge Cancer Center
2013 Jefferson St SW, 
Roanoke, VA 

Overview

Mark Kochenderfer is an Oncologist practicing medicine in Roanoke, Virginia.

Dr. Kochenderfer is highly rated in 70 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Colorectal Cancer, Breast Cancer, Neuroendocrine Tumor, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 7 clinical trials. Dr. Kochenderfer is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Carilion Medical Center
Camc Greenbrier Valley Medical Center, Inc
Lewisgale Medical Center
Lewisgale Hospital Alleghany

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lagniappe Pharmacy Services
  • OTHER MEDICARE PART D
Managed Medicaid
  • OTHER MANAGED MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Blue Ridge Cancer Center
2013 Jefferson St SW, Roanoke, VA 24014

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: Drug GC4711
Study Phase: Phase 2
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: XMT-1536 (Upifitamab Rilsodotin), Carboplatin
Study Phase: Phase 1
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
View 6 Less Clinical Trials

7 Total Publications

Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges.
Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges.
Journal: Frontiers in oncology
Published: July 17, 2025
Similar Doctors
Expertise in
59
conditions
Expertise in
59
conditions
Referral may be required

Blue Ridge Cancer Center

2013 Jefferson St SW, 
Roanoke, VA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzan Merten is an Oncologist practicing medicine in Roanoke, Virginia. Dr. Merten is highly rated in 59 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Merten is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Carilion Clinic Gynecologic Oncology

1 Riverside Cir Ste 300, 
Roanoke, VA 
 (1.7 miles away)
540-581-0160
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Janet L Osborne is an Oncologist practicing medicine in Roanoke, Virginia. Dr. L Osborne is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Malignant Mixed Mullerian Tumor, and Bladder Reconstruction. Dr. L Osborne is currently accepting new patients.

Expertise in
54
conditions
Expertise in
54
conditions
Referral may be required

Blue Ridge Cancer Care

2600 Research Center Dr # A, 
Blacksburg, VA 
 (26.3 miles away)
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerome Goldschmidt is an Oncologist practicing medicine in Blacksburg, Virginia. Dr. Goldschmidt is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Goldschmidt is currently accepting new patients.

Frequently Asked Questions about Dr. Mark D. Kochenderfer

Is Dr. Mark D. Kochenderfer a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark D. Kochenderfer is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark D. Kochenderfer specialize in?

While Dr. Mark D. Kochenderfer is a Oncology, they have specific expertise in Paget Disease of the Breast, Colorectal Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mark D. Kochenderfer participate in research or clinical trials?

Yes. Dr. Mark D. Kochenderfer has published 7 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Mark D. Kochenderfer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark D. Kochenderfer accept my insurance?

Dr. Mark D. Kochenderfer accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kochenderfer's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 59 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile